Flavocoxid/citrated zinc bisglycinate (DSC)

Drug Overview

Flavocoxid/citrated zinc bisglycinate (DSC) is a unique formulation historically utilized within the Rheumatology field. Belonging to the Medical Food drug class, it was specifically designed for the clinical dietary management of the metabolic processes associated with osteoarthritis. For patients dealing with the chronic pain and gradual joint destruction characteristic of degenerative joint disease, this formulation offered an alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs). However, it is essential for both patients and healthcare professionals to understand that this product is currently discontinued (DSC) due to serious safety concerns.

• Generic Name: Flavocoxid/citrated zinc bisglycinate
• US Brand Names: Limbrel (Discontinued)
• Drug Category: Rheumatology
• Drug Class: Medical Food
• Route of Administration: Oral capsules
• FDA Approval Status: As a Medical Food, it was not subjected to the same rigorous premarket FDA approval process as a traditional pharmaceutical drug. In late 2017, the FDA issued a strong safety alert recommending a recall due to severe, life-threatening adverse events, leading to its discontinuation in the US market.
  
  Looking for information on flavocoxid/citrated zinc bisglycinate (DSC)? Discover how this Medical Food helps manage management of osteoarthritis (limbrel). Read expert insights and medical guidelines for better health outcomes.

What Is It and How Does It Work? (Mechanism of Action)

Flavocoxid is a proprietary, plant-derived blend of two specific flavonoids: baicalin (derived from Scutellaria baicalensis) and catechin (derived from Acacia catechu), combined with citrated zinc bisglycinate to enhance absorption. While it is not a traditional Small Molecule drug or a complex Biologic, its mechanism of action relies on systemic anti-inflammatory principles.

At the cellular and molecular level, flavocoxid works as a dual-inhibitor of two critical enzymes in the body’s inflammatory cascade: cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase (5-LOX). When tissue damage occurs in an osteoarthritic joint, cell membranes release arachidonic acid. Normally, COX enzymes convert this acid into prostaglandins and thromboxanes (which cause swelling and pain), while the 5-LOX enzyme converts it into leukotrienes (which attract destructive white blood cells to the joint).

By simultaneously blocking both the COX and 5-LOX pathways, this formulation prevents the synthesis of these inflammatory mediators. Unlike a DMARD that alters the underlying immune system, or a Targeted Therapy that blocks specific cytokines like TNF-alpha to prevent synovial pannus formation, flavocoxid acts higher up in the arachidonic acid pathway. This dual-inhibition was intended to reduce localized joint inflammation, decrease the breakdown of articular cartilage, and minimize the gastrointestinal toxicity usually caused by traditional NSAIDs that only block the COX pathway.

FDA-Approved Clinical Indications

Note: Because this product was classified as a Medical Food, it was technically “indicated for the clinical dietary management” of a condition, rather than being “FDA-approved to treat” a disease.

Primary Indication

Historically, flavocoxid was indicated for the clinical dietary management of the metabolic processes of Osteoarthritis (OA).

Other Approved & Off-Label Uses

Due to its botanical anti-inflammatory properties, prior to its discontinuation, it was occasionally explored off-label for other inflammatory conditions, though never officially recognized for them:

• Rheumatoid Arthritis (mild symptom management)
• General inflammatory joint pain
• Sports-related musculoskeletal injuries

Primary Rheumatology Indications:

• Metabolic Joint Management: Designed to manage the specific dietary and metabolic needs of patients whose bodies cannot adequately regulate the arachidonic acid cascade.
• Pain Reduction: Utilized to decrease daily localized joint pain and stiffness.
• Physical Function: Intended to improve overall mobility and delay severe physical impairment in weight-bearing joints like the knees and hips.

Dosage and Administration Protocols

When actively prescribed, dosing for this Medical Food was straightforward and not strictly weight-based. However, due to its discontinued status, these protocols are strictly for historical and educational reference.

Dose Adjustments and Administration Rules:

Historically, no specific dose adjustments were mandated for mild renal impairment. However, if a patient exhibited any signs of hepatic (liver) impairment or an elevation in liver enzymes, the product was required to be stopped immediately, as no reduced dose was deemed safe for compromised livers. It was recommended to be taken with or without food, though taking it with a light meal often improved tolerability.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current and retrospective clinical study data (2020-2026) regarding flavocoxid largely focuses on analyzing its historical efficacy versus its toxicity profile. Because osteoarthritis efficacy is not measured by autoimmune ACR20/50/70 response rates or DAS28-ESR improvements, clinical trials utilized the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) to evaluate patient outcomes.

In double-blind, randomized controlled trials conducted before its recall, flavocoxid demonstrated efficacy roughly equivalent to prescription doses of naproxen (an NSAID). Patients taking the 500 mg twice-daily dose showed a statistically significant reduction in WOMAC pain, stiffness, and physical function scores over a 12-week period. Unlike a Targeted Therapy used in rheumatoid arthritis, flavocoxid did not actively reverse radiographic progression or improve Sharp scores, but backup research data suggested that dual COX/LOX inhibition could slow the ongoing structural degradation of cartilage by reducing the constant wash of inflammatory leukotrienes in the synovial fluid.

Safety Profile and Side Effects

CRITICAL SAFETY WARNING: DRUG-INDUCED LIVER INJURY AND PNEUMONITIS

While Medical Foods do not carry standard FDA “Black Box Warnings,” the FDA issued a severe public health alert regarding Limbrel. The formulation has been directly linked to life-threatening drug-induced liver injury (hepatotoxicity) and hypersensitivity pneumonitis (severe lung inflammation). Due to these unpredictable and dangerous immune-mediated reactions, the product was voluntarily recalled and discontinued.

Common Side Effects (>10%):

• Gastrointestinal discomfort, including mild nausea and dyspepsia.
• Diarrhea or changes in bowel habits.
• Mild skin rashes.

Serious Adverse Events:

• Hepatotoxicity: Sudden and severe acute liver failure, indicated by jaundice, dark urine, and massively elevated liver enzymes.
• Hypersensitivity Pneumonitis: A severe allergic reaction in the lungs causing dangerous shortness of breath, chronic cough, and fever.
• Note: It was not highly associated with cytopenias, Major Adverse Cardiovascular Events (MACE), or venous thromboembolism.

Management Strategies:

For patients who were previously on this therapy, strict laboratory monitoring schedules tracking AST, ALT, and bilirubin were mandatory. If liver enzymes became elevated, immediate cessation of the capsules was the only effective management strategy.

Research Areas

In current rheumatological research (2020-2026), the legacy of flavocoxid has sparked significant interest in the direct clinical connections between plant-derived flavonoids and joint health. Researchers are actively studying how refined, non-toxic flavonoid extracts might safely interact with synovial fibroblasts to promote cartilage preservation and influence healthy bone remodeling (the RANKL pathway). The goal is to isolate the anti-inflammatory benefits without triggering the severe autoimmune liver response seen with the original formulation.

Broader active clinical trials are focusing on the development of safer oral Small Molecule alternatives for osteoarthritis that mimic the dual COX/LOX inhibition mechanism. Generalization of this research involves creating Novel Delivery Systems, such as localized intra-articular injections or topical liposomal gels, to deliver these botanical compounds directly into the joint space. This localized approach aims to prevent Severe Disease & Systemic Involvement, ensuring that the active ingredients never reach the liver or lungs in high concentrations, completely bypassing the risk of extra-articular manifestations like hepatotoxicity or interstitial lung disease.

Disclaimer: The information regarding the discontinuation (DSC) and recall of flavocoxid/citrated zinc bisglycinate (Limbrel) by the FDA in 2017 due to risks of drug-induced liver injury (DILI) and hypersensitivity pneumonitis is current as of April 2026. This product is no longer medically recommended or available in the U.S. market. Patients should never attempt to source this discontinued product from secondary markets, and anyone who experiences unexplained fatigue, jaundice, or respiratory distress—even if they have taken herbal or “natural” supplements—must report this to their healthcare provider immediately. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before initiating any systemic anti-inflammatory protocol, a thorough baseline evaluation is necessary.

• Baseline Diagnostics: Current weight-bearing joint X-rays to assess the Kellgren-Lawrence grade of osteoarthritis, alongside a baseline Health Assessment Questionnaire (HAQ-DI) to map physical function.
• Organ Function: Strict baseline hepatic monitoring (LFTs) is absolutely critical due to the known risks of hepatotoxicity.
• Specialized Testing: Differentiating osteoarthritis from systemic autoimmune diseases is vital; therefore, Rheumatoid Factor (RF), anti-CCP antibodies, and ANA titers should be evaluated.
• Screening: Cardiovascular risk assessment and baseline pulmonary function tests if the patient has a history of respiratory issues.

Monitoring and Precautions

• Vigilance: Healthcare providers must actively monitor for any early signs of medication-induced toxicity. Sudden yellowing of the eyes (jaundice), severe right upper quadrant abdominal pain, or unexplained shortness of breath requires immediate emergency intervention, not just routine tracking of CRP/ESR.
• Lifestyle: Patients are encouraged to manage osteoarthritis actively through weight loss, low-impact exercise (swimming/cycling), and an anti-inflammatory diet. Smoking cessation is strongly recommended to protect lung health and reduce systemic inflammation.

“Do’s and Don’ts” list:

• DO inform your doctor of every supplement, vitamin, and Medical Food you take, as “natural” products can still cause severe organ damage.
• DO seek immediate medical attention if you experience sudden fatigue, dark urine, or yellowing of the skin while taking any joint supplement.
• DO engage in daily physical therapy exercises to keep your joints flexible.
• DON’T attempt to purchase discontinued medications or leftover stock from unverified online pharmacies.
• DON’T combine multiple oral anti-inflammatory supplements without medical supervision, as this massively increases the risk of liver injury.

Legal Disclaimer

The medical information provided in this document is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. This document discusses a discontinued product. Always seek the advice of your physician, rheumatologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, the management of osteoarthritis, or before beginning or altering any treatment plan.